Navigation Links
Kiadis Pharma Receives Two Orphan Drug Designations for Reviroc(TM) From the FDA
Date:12/8/2008

AMSTERDAM, December 8 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma announces today that the U.S. Food and Drug Administration (FDA) has granted its product Reviroc(TM) Orphan Drug Designations (ODD) for the treatment of two types of Non-Hodgkin Lymphoma (NHL). One ODD has been granted for diffuse large B-cell lymphoma and the other one for the treatment of follicular lymphoma. Reviroc(TM) is under development for the elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients.

"This is an important strategic milestone in the development of Reviroc(TM) and we are very pleased with the orphan drug designations received from the FDA," says Dr. Manja Bouman, Chief Executive Officer of Kiadis Pharma.

The FDA's orphan drug designation is reserved for new therapies being developed to treat diseases or conditions that affect fewer than 200,000 people in the United States. The orphan drug designation provides for an accelerated review process, tax benefits, exemption from user fees and a seven-year period of market exclusivity in the US after product approval.

About Reviroc(TM)

Reviroc(TM) is being developed as a treatment that eliminates blood cancer cells from autologous transplants for patients with end stage blood cancer. An autologous transplant uses the patient's own bone marrow to serve as a graft. Bone marrow transplants are broadly recognized as a treatment option for patients suffering from blood cancers, such as leukemia and lymphoma. One of the limitations of autologous bone marrow transplantations is the high relapse rate associated with this treatment. This is often caused by the presence of cancer cells in the transplant. Reviroc(TM) has been developed to remove tumor cells from the graft.

About Kiadis Pharma

Kiadis Pharma is an oncology focused biopharmaceutical development company with cell based products in clinical development. The company develops products that offer novel treatment options for terminally ill cancer patients and address significant unmet medical needs. The key focus indication for Kiadis Pharma is limitations and complications of bone marrow transplantation procedures performed in blood cancer patients. Kiadis Pharma is headquartered in Amsterdam, The Netherlands with facilities in Groningen, The Netherlands and Montreal, Canada. For more information about Kiadis Pharma, please visit http://www.kiadis.com.


'/>"/>
SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Kiadis Pharma Announces Promising Phase II Clinical Trial Results for Reviroc
2. Kiadis Pharma Announces Collaboration With the Julius Maximilians University of Wurzburg, Germany
3. Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations
4. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... May 6, 2016  Hill-Rom Holdings, Inc. (NYSE: ... declared a fiscal year 2016 third quarter dividend of $0.17 per ... over the amount paid a year ago. The dividend ... of the close of business on June 10, 2016. ... Hill-Rom is a leading global medical technology company with ...
(Date:5/6/2016)... 6, 2016 Appoints Susanta ... its Application to Drug Development Including Development of Radiopharmaceuticals ... the life sciences consulting firm, today announced that it ... Associate Partner in its Cambridge, MA ... PhD, in the firm,s Medical Imaging consulting practice and ...
(Date:5/5/2016)... 2016 Global NASH market ... with rise in obesity will fuel the demand ... few years. The NASH Market is growing at ... account of rising number of obesity among young ... market with no FDA approved therapeutics. Antioxidants, anti-diabetic ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... 06, 2016 , ... Norwood Insurance Group, serving families of ... their ongoing community enrichment program. The current campaign is being extended to continue ... more months of treatments, leaving his family in great need of financial assistance. ...
(Date:5/6/2016)... ... May 06, 2016 , ... ... charity program created to support and assist the people of their local community. ... with nonprofit organizations and community leaders. Their desire is to bring awareness to ...
(Date:5/6/2016)... ... May 06, 2016 , ... DrugDev President ... the way the pharmaceutical industry conducts clinical trials. This month Ibs was named No. ... in pharma, and he was honored as a Tech Disruptor by the Philadelphia Business ...
(Date:5/6/2016)... ... 06, 2016 , ... The joy associated with Mother’s Day is mixed with worry and fear ... units (NICUs) across the country. For the first time ever, the March of Dimes ... who spend their Mother’s Day beside a crib surrounded by lifesaving equipment or peering through ...
(Date:5/6/2016)... ... May 06, 2016 , ... Featured cast and producers of ... address at the 2016 Learning Summit , June 12-15, in Paradise Valley, ... Their stories—of complicated family issues, financial difficulties, and other personal obstacles—are the stories ...
Breaking Medicine News(10 mins):